What is the latest SUPRIYA stock price?
The latest stored price for SUPRIYA is Rs 837.30 as of 2026-07-20.
gimli
SUPRIYA stock AI analysis
SUPRIYA Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
SUPRIYA LIFESCIENCE LTD is a small-cap stock in Healthcare. This Gimli page shows the latest available SUPRIYA price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹837.30
1W return
-0.91%
1M return
-10.18%
3M return
+35.09%
6M return
+15.68%
1Y return
+17.71%
Market cap
₹6,738.82 cr
PE
32.22
PB
5.63
ROE
+19.06%
ROCE
+25.09%
RSI
42.37
Turnover
₹8.64 cr
Why it can matter in screens
- Momentum: SUPRIYA is below 50DMA, above 200DMA; RSI is 42.37.
- Returns: 1D +1.04%, 1W -0.91%, 1M -10.18%, 3M +35.09%, 1Y +17.71%.
- Trend levels: 52W high ₹1,052.50, 52W low ₹553.35, off high -20.45%.
- Liquidity: latest turnover is ₹8.64 cr; volume vs 20D is +0.22%.
- Valuation/profitability: PE 32.22, PB 5.63, ROE +19.06%, ROCE +25.09%.
- Growth: 3Y sales CAGR +22.44%, 3Y profit CAGR +32.51%.
Quick Answers
Is SUPRIYA above its 50DMA and 200DMA?
SUPRIYA is below 50DMA, above 200DMA. The latest 50DMA is 868.89 and the latest 200DMA is 742.19.
What are SUPRIYA PE, ROE and ROCE?
SUPRIYA has PE 32.22, ROE +19.06%, and ROCE +25.09% in Gimli's latest available snapshot.
How has SUPRIYA performed recently?
SUPRIYA has returned -10.18% over 1 month, +35.09% over 3 months, and +17.71% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 276.53 cr | 101.09 cr | 74.23 cr | 9.22 |
| 2025-12-31 | 206.44 cr | 74.23 cr | 49.67 cr | 6.17 |
| 2025-09-30 | 199.83 cr | 75.37 cr | 50.43 cr | 6.27 |
| 2025-06-30 | 145.07 cr | 54.38 cr | 34.79 cr | 4.32 |
| 2025-03-31 | 184.11 cr | 70.56 cr | 50.38 cr | 6.29 |
| 2024-12-31 | 185.65 cr | 68.05 cr | 46.78 cr | 5.82 |
| 2024-09-30 | 166.10 cr | 67.23 cr | n/a | 5.71 |
| 2024-06-30 | 160.63 cr | 64.77 cr | 44.64 cr | 5.54 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 827.88 cr | 305.08 cr | 209.12 cr | 25.98 |
| 2025-03-31 | 696.49 cr | 270.59 cr | 187.96 cr | 23.35 |
| 2024-03-31 | 557.41 cr | 185.20 cr | 119.11 cr | 14.80 |
| 2023-03-31 | 451.01 cr | 136.98 cr | 89.86 cr | 11.16 |
| 2022-03-31 | 537.63 cr | 220.17 cr | 151.81 cr | 18.86 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 1,357.11 cr | 37.55 cr | 5.43 cr | 1,197.73 cr |
| 2025-03-31 | 1,112.31 cr | 76.00 cr | 5.38 cr | 996.76 cr |
| 2024-03-31 | 921.45 cr | 68.35 cr | 5.49 cr | 815.37 cr |
| 2023-03-31 | 820.28 cr | 85.25 cr | 22.47 cr | 699.46 cr |
| 2022-03-31 | 734.76 cr | 165.78 cr | 27.41 cr | 615.69 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 185.77 cr | 33.53 cr | n/a |
| 2025-03-31 | 164.68 cr | 2.30 cr | n/a |
| 2024-03-31 | 113.31 cr | -32.35 cr | n/a |
| 2023-03-31 | 63.60 cr | -44.30 cr | n/a |
| 2022-03-31 | 48.80 cr | -11.10 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +68.30% | +5.16% | +5.70% | +1.33% | +20.84% | +0.00% |
| 2025-12-31 | +68.30% | +5.20% | +5.01% | +0.67% | +21.50% | +0.00% |
| 2025-09-30 | +68.30% | +5.46% | +5.22% | +0.68% | +21.02% | +0.00% |
| 2025-06-30 | +68.30% | +6.78% | +4.86% | +0.68% | +20.06% | +0.00% |
| 2025-03-31 | +68.30% | +7.19% | +4.26% | +0.66% | +20.26% | +0.00% |
| 2024-12-31 | +68.30% | +6.52% | +4.92% | +0.67% | +20.26% | +0.00% |
| 2024-09-30 | +68.30% | +6.03% | +5.45% | +0.62% | +20.23% | +0.00% |
| 2024-06-30 | +68.30% | +4.95% | +5.48% | +0.13% | +21.27% | +0.00% |
| 2024-03-31 | +68.30% | +5.36% | +5.30% | +0.05% | +21.04% | +0.00% |
| 2023-12-31 | +68.30% | +4.56% | +5.39% | +0.04% | +21.76% | +0.00% |
| 2023-09-30 | +68.30% | +5.34% | +7.17% | +1.74% | +19.19% | +0.00% |
| 2023-06-30 | +68.30% | +5.73% | +7.55% | +2.14% | +18.43% | +0.00% |
| 2023-03-31 | +68.28% | +5.65% | +7.65% | +2.38% | +18.42% | +0.00% |
| 2022-12-31 | +68.24% | +6.24% | +7.89% | +2.38% | +17.63% | +0.00% |
| 2022-09-30 | +68.24% | +6.79% | +8.88% | +2.38% | +16.09% | +0.00% |
| 2022-06-30 | +68.24% | +0.00% | +16.32% | n/a | n/a | +0.00% |
| 2022-03-31 | +68.24% | +0.00% | +14.86% | n/a | n/a | n/a |
| 2021-12-31 | +68.24% | +0.00% | +18.20% | n/a | n/a | +0.00% |
| 2021-12-23 | +68.24% | +0.00% | +22.36% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 469,405.90 cr | 40.823336 | +14.71% | +15.52% |
| DIVISLAB | DIVI S LABORATORIES LTD | 194,269.92 cr | 75.650281 | +16.19% | +8.71% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 169,405.46 cr | 78.319677 | +17.18% | +42.14% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,040.28 cr | 65.380043 | +21.03% | +21.93% |
| CIPLA | CIPLA LTD | 116,452.52 cr | 30.005339 | +11.79% | -2.75% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,616.29 cr | 23.056854 | +17.93% | +17.85% |
| LUPIN | LUPIN LIMITED | 113,320.96 cr | 21.221472 | +26.83% | +28.27% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 107,290.40 cr | 74.382732 | +14.33% | -9.32% |
Try these prompts
- Analyze SUPRIYA LIFESCIENCE with valuation, momentum and industry peers
- Compare SUPRIYA with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare SUPRIYA with other Healthcare stocks
Data snapshot: 2026-07-20. Not investment advice.